Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 9 SODIUM CHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus NICARDIPINE HYDROCHLORIDE IN 0 9 SODIUM CHLORIDE.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs NICARDIPINE HYDROCHLORIDE IN 0.9% SODIUM CHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into myocardial and vascular smooth muscle cells, resulting in vasodilation and reduced systemic vascular resistance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: Initial rate 5 mg/hour, titrate by 2.5 mg/hour every 5-15 minutes to a maximum of 15 mg/hour. For hypertension, typical maintenance 3-5 mg/hour.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal elimination half-life is 8.6 hours (range 6–10 hours). In patients with hepatic impairment, half-life may be prolonged up to 14 hours. No significant change in renal impairment.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites are excreted renally and fecally. Fecal excretion accounts for approximately 35% of total elimination.
Category C
Category A/B
Electrolyte
Electrolyte